Skip to content

Clinical Trial to Preliminarily Assess the Safety and Feasibility of SAT-014, a Software for Alleviating Symptoms of Trauma and Stress-related Disorders

An Open-label, Randomized, Controlled, Exploratory Clinical Trial to Preliminarily Assess the Safety and Feasibility of SAT-014, a Software for Alleviating Symptoms of Trauma and Stress-related Disorders

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06439407
Enrollment
20
Registered
2024-06-03
Start date
2024-01-03
Completion date
2024-08-30
Last updated
2024-12-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Posttraumatic Stress Disorder

Brief summary

Failure to adapt to stress leads to functional impairments in various areas, including social, occupational, educational, and other significant domains, necessitating therapeutic intervention. Interventions through mobile app in the form of software can provide a new alternative for alleviating symptoms caused by psychological trauma by increasing accessibility to early intervention for trauma patients. This study aims to preliminarily assess the safety and feasibility of a psychological traum intervention by developing SAT-014 to help patients with trauma and stress-related disorder continue effective treatment in a stable environment.

Interventions

DEVICESAT-014(Software as Medical Device)

SAT-014(Software as Medical Device) + maintain previous treatment

Sponsors

S-Alpha Therapeutics, Inc.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

1. Adults (19 years and older) 2. Have experienced clinically significant psychological trauma within the 6 months prior to screening visit 3. Met the diagnostic criteria for Post-Traumatic Stress Disorder (PTSD) or Adjustment Disorder (AD) category as evaluated by MINI (Mini-International Neuropsychiatric Interview) 4. Score between 17 and 38 points on the IES-R (Impact of Event Scale-Revised) 5. Score of 4 or less on CGI (Clinical Global Impression) 6. Capable of complying the activity instructions provided the app

Exclusion criteria

1. Have been diagnosed with schizophrenia, bipolar disorder, and psychotic disorder 2. Have been diagnosed with neurodevelopmental disorder, neurocognitive disorder, or organic mental disorder 3. Severe depression (PHQ-9 score of 20 or greater) 4. Comorbid with severe personality disorder 5. Diagnosed with substance use disorder excluding nicotine and caffeine and with severe alcohol use disorder 6. Have made a suicide attempt within 3 months and are judged to be at high risk for suicide by a psychiatrist 7. Pregnant or lactating 8. Currently participating in another clinical trial or have participated in another trial within 90 days from screening 9. Others deemed unsuitable for participation in this clinical trial at the discretion of the investigator due to ethical concerns or potential impact on the trial outcome

Design outcomes

Primary

MeasureTime frameDescription
Change in IES-R (Impact Event Scale-Revised) scoreBaseline, 3weeks, 6weeks, 10weeksThe Korean version of the Impact Event Scale-Revised (IES-R) consists of 22 items each rated on a 5-point scale ranging from 0 to 4. The total score ranges from 0 to 88, with higher scores indicating a greater risk of post-traumatic stress disorder and a worse outcome.
Change in PCL-5 (PTSD Checklist-5) scoreBaseline, 3weeks, 6weeks, 10weeksThe PTSD Checklist for DSM-5 (PCL-5) consists of 20 items, each rated on a scale from 0 to 4. The total score ranges from 0 to 80, with higher scores indicating greater distress due to symptoms related to past stressful experiences and a worse outcome.
Change in GAD-7 (Generalized Anxiety Disorder 7 item scale) scoreBaseline, 3weeks, 6weeks, 10weeksThe Generalized Anxiety Disorder 7-item scale (GAD-7) consists of 7 items, each rated on a scale from 0 to 3. The total score ranges from 0 to 21, with higher scores indicating more severe anxiety symptoms and a worse outcome.
Change in BAI (Beck Anxiety Inventory) scoreBaseline, 3weeks, 6weeks, 10weeksThe Beck Anxiety Inventory (BAI) consists of 21 items, each rated on a scale from 0 to 3. The total score ranges from 0 to 63, with higher scores indicating more severe anxiety symptoms and a worse outcome.
Change in PHQ-9 (Patient Health Questionnaire-9; depression screening tool) scoreBaseline, 3weeks, 6weeks, 10weeksThe Patient Health Questionnaire-9 (PHQ-9) consists of 9 items, each rated on a scale of 0 to 3. The total score ranges from 0 to 27, with higher scores indicating more severe symptoms and a worse outcome.
Change in QIDS-SR (Quick Inventory of Depressive Symptomatology-Self Report) scoreBaseline, 3weeks, 6weeks, 10weeksThe Quick Inventory of Depressive Symptomatology-Self Report (QIDS-SR) consist of 16 items, each rated on a scale of 0 to 3. It evaluates responses to 16 items based on criteria for nine depressive symptoms. The total score ranges from 0 to 27, with higher scores indicating more severe symptoms and a worse outcome.
Change in CGI (Clinical Global Impression) scoreBaseline, 3weeks, 6weeks, 10weeksThe CGI consists of two items: (a) the clinician's overall impression of the patient's severity of illness and (b) global improvement over time. The severity of illness is rated on a scale from 1 to 7, with a higher score indicating more severe illness and a worse outcome. Global improvement is also rated on a scale from 1 to 7, with a higher score indicating a worse outcome.

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026